Adlai Nortye initiates trial for AN4035 in RAS-mutated advanced cancers
Adlai Nortye Biopharma is conducting a clinical trial to evaluate the safety and tolerability of AN4035 in patients with advanced solid tumors harboring RAS mutations and high CEACAM5 expression.
Phase III
Oncology / RAS Mutations
Status
Active
Sponsor
Adlai Nortye Biopharma
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the AN4035 trial by Adlai Nortye represents a significant step in addressing the unmet need for effective therapies in RAS-mutated advanced cancers. The outcomes of this trial could reshape competitive dynamics in oncology and influence strategic partnerships.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for safety and efficacy, particularly the recommended dose and any observed anti-cancer activity.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.